arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

NEXGEL, INC.

NXGL
$0.26 ▼ -0.01 (-2.19%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
35 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

NEXGEL, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.3M
Dividend Yield
Revenue Growth 27.8%
Op. Margin -68.0%
ROIC -40.0%
FCF / Share $-0.24
Trailing P/E
Price / Book 0.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.69M
↑ +27.8%
Net Income Profit after all expenses
$-3.63M
↓ -446.6%
Operating Margin Operating profit as % of sales
-68.0%
↓ -88.0% 8th
FCF / Share Free cash flow per share
$-0.24
↓ -296.8%
Long-Term Debt Long-term obligations
$563.00K
↓ -4.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
13
Financial Health
78
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters